Osteoarthritis pathophysiology:Therapeutic target discovery may require a multifaceted approach

Vincent, Tonia L., Alliston, Tamara, Kapoor, Mohit, Loeser, Richard F., Troeberg, Linda and Little, Christopher B. (2022) Osteoarthritis pathophysiology:Therapeutic target discovery may require a multifaceted approach. Clinics in Geriatric Medicine, 38 (2). pp. 193-219. ISSN 0749-0690

[img] PDF (CH0002_Vincent) - Accepted Version
Restricted to Repository staff only until 7 April 2023.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Request a copy
Item Type: Article
Additional Information: Funding Information: T.L. Vincent has received research funding to support the STEpUP OA Consortium from Pfizer , Galapagos , Fidia , Novartis , BioSplice . T. Alliston, M. Kapoor and L. Troeberg have nothing to disclose. R.F. Loeser has received consulting fees from Unity Biotechnology. C.B. Little has provided consulting advice for Merck Serono and Galapagos Pharmaceuticals, and has received research funding from numerous pharmaceutical companies through specific services/testing contract research agreements between and managed by The University of Sydney or the Northern Sydney Local Health District. Funding Information: The research of the authors related to the specific topics explored in this review were supported by funding from numerous sources: T.L. Vincent Center for OA Pathogenesis versus Arthritis (grant no. 20205 and 21,621); M. Kapoor Tier 1 Canada Research Chair Award (#950?232237) and Tony and Shari Fell Platinum Chair in Arthritis Research; R.F. Loeser National Institute on Aging RO1 AG044034; L. Troeberg VA grants 21,776 and 22,194; C.B. Little Australian National Health and Medical Research Council (NHMRC: Project Grant APP1045890), the Hillcrest Foundation through Perpetual Philanthropies, and Arthritis Australia.T.L. Vincent has received research funding to support the STEpUP OA Consortium from Pfizer, Galapagos, Fidia, Novartis, BioSplice. T. Alliston, M. Kapoor and L. Troeberg have nothing to disclose. R.F. Loeser has received consulting fees from Unity Biotechnology. C.B. Little has provided consulting advice for Merck Serono and Galapagos Pharmaceuticals, and has received research funding from numerous pharmaceutical companies through specific services/testing contract research agreements between and managed by The University of Sydney or the Northern Sydney Local Health District. Funding Information: The research of the authors related to the specific topics explored in this review were supported by funding from numerous sources: T.L. Vincent Center for OA Pathogenesis versus Arthritis (grant no. 20205 and 21,621 ); M. Kapoor Tier 1 Canada Research Chair Award (#950–232237) and Tony and Shari Fell Platinum Chair in Arthritis Research; R.F. Loeser National Institute on Aging RO1 AG044034 ; L. Troeberg VA grants 21,776 and 22,194; C.B. Little Australian National Health and Medical Research Council (NHMRC: Project Grant APP1045890), the Hillcrest Foundation through Perpetual Philanthropies, and Arthritis Australia.
Uncontrolled Keywords: aging,bone,cartilage,fibrosis,inflammation,osteoarthritis,pathophysiology,treatment targets,geriatrics and gerontology ,/dk/atira/pure/subjectarea/asjc/2700/2717
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 20 Apr 2022 09:30
Last Modified: 11 May 2022 00:45
URI: https://ueaeprints.uea.ac.uk/id/eprint/84696
DOI: 10.1016/j.cger.2021.11.015

Actions (login required)

View Item View Item